IMPDH1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1152160	0.62	18/20
SCHEMBL1153339	0.59	18/20
SCHEMBL1152649	0.56	18/20
SCHEMBL1152729	0.83	17/20
SCHEMBL1152849	0.79	17/20
SCHEMBL1153315	0.72	17/20
SCHEMBL1153336	0.67	17/20
SCHEMBL1153452	0.67	17/20
SCHEMBL1152538	0.64	17/20
SCHEMBL1152268	0.60	17/20
SCHEMBL1152869	0.60	17/20
SCHEMBL1152057	0.56	17/20
SCHEMBL1152477	1.00	16/20
SCHEMBL1153274	0.73	16/20
SCHEMBL679270	0.72	16/20
SCHEMBL679271	0.72	16/20
SCHEMBL1153159	0.68	16/20
SCHEMBL1153350	0.68	16/20
SCHEMBL1153362	0.60	16/20
SCHEMBL1153706	0.58	16/20

Clinical trials — most relevant to IMPDH1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis	PHASE3	COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer	PHASE2	UNKNOWN
Antifolate Effectiveness in Arthritis	PHASE2	COMPLETED
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene	PHASE2	COMPLETED
Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab	PHASE2	UNKNOWN
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome	PHASE2	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Mycophenolate Mofetil in Systemic Sclerosis	PHASE1	COMPLETED
IMPase in Treatment-resistant Depression	PHASE1	UNKNOWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines	PHASE1	COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells	PHASE1	RECRUITING
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors	nan	WITHDRAWN
The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line	nan	UNKNOWN
Specific Genotypes/Phenotypes of Pneumocystis Jirovecii in Solid Organ Transplant Recipients: Potential Involvement of Mycophenolic Acid	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.	nan	COMPLETED
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart	nan	UNKNOWN
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E	nan	UNKNOWN
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD	nan	COMPLETED
Investigation of ADA Enzyme Deficiency	nan	UNKNOWN
Mechanistic Studies of Teriflunomide in RRMS	nan	COMPLETED
Genetic Variants and Regulation of Specialized Pro-resolving Mediator	nan	RECRUITING
Correlation of Genetic Polymorphism of Azathioprine Metabolizing Enzymes and Correlation to Clinical Adverse Effects	nan	COMPLETED
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer	nan	COMPLETED
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IMPDH1 binder may also engage these)

Protein	Name	Similarity
A0JNA3	—	1.000	A0JNA3 →
D3ZLZ7	—	1.000	D3ZLZ7 →
P50096	—	1.000	P50096 →
E9PU28	—	1.000	E9PU28 →
Q5RGV1	—	1.000	Q5RGV1 →
Q3SWY3	—	1.000	Q3SWY3 →
F6S675	—	1.000	F6S675 →
P24547	—	1.000	P24547 →
O14344	—	1.000	O14344 →
B0UXP9	—	1.000	B0UXP9 →
IMPDH2	Inosine-5'-monophosphate dehydrogenase 2	1.000	landscape →
P12269	—	1.000	P12269 →
Q6GMG5	—	1.000	Q6GMG5 →
P38697	—	1.000	P38697 →
P50095	—	1.000	P50095 →
Q8F4Q4	—	1.000	Q8F4Q4 →
P50094	—	1.000	P50094 →
P68839	—	1.000	P68839 →
Q9L6B7	—	1.000	Q9L6B7 →
F7CYY5	—	1.000	F7CYY5 →
W6QIT2	—	1.000	W6QIT2 →
Q8KCW4	—	1.000	Q8KCW4 →
Q7SFX7	—	1.000	Q7SFX7 →
P44334	—	1.000	P44334 →
Q4WHZ9	—	1.000	Q4WHZ9 →
P31002	—	1.000	P31002 →
Q9GZH3	—	0.999	Q9GZH3 →
P21620	—	0.999	P21620 →
P0DB89	—	0.999	P0DB89 →
P0DB88	—	0.999	P0DB88 →